Skip to main content
. 2019 Dec 6;2019:6304058. doi: 10.1155/2019/6304058

Table 3.

Effects of myricetin on echocardiographic parameters.

CON Myr AB AB+Myr
N 10 10 10 10
HR (bpm) 496 ± 15 487 ± 27 492 ± 33 478 ± 34
IVSd (mm) 0.79 ± 0.05 0.78 ± 0.05 0.86 ± 0.03 0.81 ± 0.06#
LVEDd (mm) 3.88 ± 0.23 3.73 ± 0.14 4.56 ± 0.40 3.97 ± 0.33#
LVEPWd (mm) 0.77 ± 0.05 0.79 ± 0.05 0.89 ± 0.05 0.83 ± 0.05#
IVDs (mm) 1.12 ± 0.04 1.15 ± 0.08 1.2 ± 0.07 1.19 ± 0.12
LVEDs (mm) 2.05 ± 0.18 1.98 ± 0.09 3.1 ± 0.34 2.4 ± 0.49#
LVEPWs (mm) 1.13 ± 0.05 1.2 ± 0.06 1.16 ± 0.05 1.16 ± 0.12
EF (%) 81.5 ± 1.87 80.83 ± 2.4 63.08 ± 2.71 71.45 ± 3#
FS (%) 45 ± 4.38 46.77 ± 2.15 31.67 ± 2.42 37.8 ± 2.54#

HR: heart rate; IVSd: interventricular septal thickness (IVS) at diastole; IVSs: IVS at systole; LVEDd: LV end-diastolic diameter; LVEDs: LV end-systolic diameter; LVPWd: LV end-diastolic posterior wall thickness; LVPWs: LV end-systolic posterior wall thickness; LVEF: LV ejection fraction; FS: fractional shortening. p < 0.05 versus the CON group or the Myr group, #p < 0.05 versus the AB+Myr group.